ComplyRx
Built by ComplyRx

Compare clinical trial pipelines, export for presentations

amivantamab (16) vs zanubrutinib (16)29 active2017–2033
amivantamabzanubrutinib
Key
Actual date
Anticipated
Forecast to primary completion
RecruitingActive, not recruitingNot yet recruitingCompletedSuspendedUnknown status
'17
'19
'21
'23
'25
'27
'29
'31
'33
amivantamab
BoBP2
MARIPOSAP3
PAPILLONP3
MARIPOSA-2P3
PALOMA-3P3
PALOMA-2P2
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)P2
COCOONP2
OrigAMI-2P3
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)P2
OrigAMI-3P3
COPERNICUSP2
An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment.P2
OrigAMI-5P3
Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune SystemP2
AmiCAREP4
zanubrutinib
ASPENP3
Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)P2
MAGNOLIAP2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)P2
CLL-RT1P2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic LymphomaP2
Zanubrutinib and Eltrombopag as Second-line Treatment in Adults With Primary Immune ThrombocytopeniaP2
Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based ObinutuzumabP2
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)P3
MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLLP2
The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell LymphomaP3
Epco, Zanu, Ritux for R/R FL or MZLP2
Benefit VAP2
ZBR in WMP2
ZR2 Versus R2 Regimen in the Treatment of Newly Diagnosed Follicular LymphomaP2
ZSP2

Upcoming readouts

22 ahead · 2 drugs

Select a trial to load its full ClinicalTrials.gov record.

Trial Pipeline · How it works

Search, compare, export.

Three steps from drug name to a presentation-ready pipeline view, with live trial data, side by side.

  1. 01 · SEARCH

    Search drugs

    Type a drug name and see the phase 2-4 trials from ClinicalTrials.gov.

  2. 02 · COMPARE

    Compare timelines

    See start dates, primary completions, and status on one timeline, up to five drugs at once.

  3. 03 · EXPORT

    Export for your deck

    Download a branded PNG or PDF. Share the URL. Every comparison state is linkable.

FAQ

Where does the data come from?
All trial data is sourced from ClinicalTrials.gov (CTGov). Results are cached for up to 6 hours so repeat loads stay fast.
Is this free?
Yes. Compare up to five drugs and export PNG or PDF at no cost. Export requires a one-time email to join the ComplyRx waitlist.
What is ComplyRx?
ComplyRx is an all-in-one marketing/competitive intelligence platform for organisations and individuals that work in healthcare, life sciences, and the pharmaceutical industry.
Join the waitlist

Be the first to access ComplyRx

We'll let you know as soon as your spot opens to use ComplyRx.

By joining, you agree to our Privacy Policy.